CTX211 / CRISPR Therap, Vertex - LARVOL DELTA

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: CRISPR Therapeutics AG | Phase classification: P1/2 ➔ P1 | N=40 ➔ 5 | Recruiting ➔ Terminated | Trial primary completion date: Apr 2025 ➔ Aug 2025; Patients to be followed up in the VCTX-201 study

Enrollment change • First-in-human • Phase classification • Trial primary completion date • Trial termination • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones (GlobeNewswire) - "Progress continues in regenerative medicine, with ongoing efforts to develop innovative therapies, including the clinical trial for CTX211 in Type 1 diabetes (T1D) and subsequent next generation programs...The Company anticipates providing an update in 2025."

Clinical • Type 1 Diabetes Mellitus

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: CRISPR Therapeutics AG | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: CRISPR Therapeutics AG

New P1/2 trial • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus